Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial

BACKGROUND: Venetoclax with hypomethylating agents is a new standard of care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) who are 75 years or older, or unfit for intensive chemotherapy. Pharmacodynamic studies have suggested superiority of the longer 10-day regimen of decitabi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet Haematol
Hoofdauteurs: DiNardo, Courtney D., Maiti, Abhishek, Rausch, Caitlin R., Pemmaraju, Naveen, Naqvi, Kiran, Daver, Naval G., Kadia, Tapan M., Borthakur, Gautam, Ohanian, Maro, Alvarado, Yesid, Issa, Ghayas C., Montalban-Bravo, Guillermo, Short, Nicholas J., Yilmaz, Musa, Bose, Prithviraj, Jabbour, Elias J., Takahashi, Koichi, Burger, Jan, Garcia-Manero, Guillermo, Jain, Nitin, Kornblau, Steven M., Thompson, Philip A., Estrov, Zeev, Masarova, Lucia, Sasaki, Koji, Verstovsek, Srdan, Ferrajoli, Alessandra, Weirda, William G., Wang, Sa A., Konopleva, Sergej, Chen, Zhining, Pierce, Sherry A., Ning, Jing, Qia, Wei, Ravandi, Farhad, Andreeff, Michael, Welch, John S., Kantarjian, Hagop M., Konopleva, Marina Y.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2020
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549397/
https://ncbi.nlm.nih.gov/pubmed/32896301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(20)30210-6
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items